SEC Filing Summary
Issuer and period: The supplied filing is Apollo Medical Holdings, Inc.’s Form 10-K for the fiscal year ended December 31, 2018, filed March 18, 2019. It is an annual report, not a standalone fourth-quarter filing. The filing does not identify the issuer as Astrana Health, Inc.; confirm the company and filing match the requested security.
Business context
ApolloMed was a California-focused, physician-centric healthcare management and delivery company. It coordinated care for nearly 1.0 million patients through affiliated physician groups, more than 6,000 contracted physicians, management services, clinics, hospitalists, and its Medicare Next Generation ACO (NGACO). Its results consolidate affiliated physician entities, including variable interest entities (VIEs), so consolidated revenue and cash do not necessarily represent funds available to the parent.
Financial results
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Revenue | $519.9 million | $356.4 million |
| Operating income | $88.4 million | $35.1 million |
| Net income | $60.3 million | $45.8 million |
| Net income attributable to ApolloMed | $10.8 million | $25.8 million |
| Basic / diluted EPS | $0.33 / $0.29 | $1.01 / $0.90 |
| Cash from operations | $25.5 million | $51.8 million |
| Cash and cash equivalents at year-end | $106.9 million | $99.7 million |
| Working capital at year-end | $100.8 million | $34.6 million |
Revenue grew 46%; operating income grew 152%; and consolidated net income grew 32%. Approximate operating margin rose to 17.0% from 9.9%, while net margin was 11.6% versus 12.9%. The parent-attributable result fell 58%, principally reflecting substantially higher income allocated to noncontrolling interests. These comparisons are not fully like-for-like: 2017 results include ApolloMed’s operations only from the December 2017 merger closing, whereas 2018 includes the combined company for the full year.
Revenue growth included higher capitation ($344.3 million, up 26%), risk-pool settlements and incentives ($100.9 million, up 126%), management fees ($49.7 million, up 84%), and fee-for-service revenue ($19.7 million, up 165%). Management cited membership and rate growth, favorable utilization and risk-pool results, added patient groups, and acquired operations. Costs of services rose 32% to $361.1 million; general and administrative costs rose 65% to $43.4 million.
Operating cash flow declined by about half despite higher net income. Investing used $25.2 million, including $16.7 million for equity-method investments and $7.5 million of loan advances; financing used $11.2 million, including dividends and share repurchases. Year-end total liabilities were $106.3 million. Borrowings included $13.0 million outstanding on a related-party credit facility; the filing also disclosed an ICC bank loan of about $0.04 million, repaid in January 2019. The company reported $0.7 million available under the drawn NMM facility, plus separate undrawn facilities subject to their terms and restrictions.
Material changes and unusual items
- The company adopted ASC 606 in 2018 using the modified retrospective method. For FY 2018, it increased reported revenue by $36.4 million, net income by $26.2 million, and diluted EPS by $0.08 compared with the amounts that would have been reported under the prior standard. The 2017 comparative was not restated.
- CMS determined that approximately $34.5 million of NGACO payments for performance year 2017 were excess; ApolloMed refunded the amount in December 2018. It had been accrued as a medical liability at year-end 2017.
- The company recorded $5.9 million of 2017 NGACO risk-pool savings as revenue in 2018. It also recorded $3.8 million of goodwill impairment related to Maverick Medical Group and a $3.9 million allowance for doubtful management-fee receivables.
- A settlement with former APCN shareholders involved approximately $4.2 million paid by ApolloMed and $1.7 million by APC to repurchase shares; ApolloMed recorded about $0.8 million of settlement expense.
- Equity-method investment losses increased to $8.1 million, including a $6.0 million loss allocated from Universal Care, Inc. (UCI).
Liquidity, outlook, and risks
Management said available liquidity was sufficient to fund operations at least through March 2020. CMS AIPBP payments were approximately $5.5 million per month from October 2018 and increased to approximately $8.3 million per month effective January 1, 2019. The NGACO participation agreement was renewed for 2019, with an option for 2020; continued participation and payment levels remain subject to CMS requirements and performance. The filing gives no formal earnings or revenue guidance.
A key reporting concern is the material weakness in controls over review of externally prepared full-risk-pool reports used to recognize revenue. Management concluded internal control over financial reporting was ineffective, and the auditor issued an adverse opinion on those controls; the financial-statement audit opinion was unqualified. Management began remediation and expected to implement new review procedures during 2019, with no assurance of successful remediation.
Other significant risks include concentration in four payors (61.5% of 2018 revenue), exposure to capitation and medical-cost risk, uncertainty over NGACO benchmarks and reconciliation, CMS program changes or termination, California healthcare regulation and corporate-practice-of-medicine restrictions, related-party arrangements, and collection and estimation risks. The company reported a pending Prospect arbitration seeking damages exceeding $5 million; ApolloMed disputed the allegations, and the loss range was not estimable. It also disclosed a securities-law investigation related to the merger; no lawsuit had been filed by the identified firm as of the report date.
Most important facts for investors to verify
- Confirm the filing belongs to the intended issuer: the document names Apollo Medical Holdings, Inc., not Astrana Health, Inc.
- Assess how ASC 606’s $36.4 million revenue uplift and $26.2 million net-income uplift affect interpretation of reported growth.
- Review the quality, collectability, and timing of risk-pool receivables, including the material weakness in validating external reports.
- Check NGACO reconciliation, medical-cost performance, CMS payment levels, financial-guarantee requirements, and ongoing program eligibility.
- Evaluate the gap between consolidated earnings and ApolloMed-attributable earnings, alongside cash-flow conversion and restricted or VIE-level cash.
- Review payor concentration, related-party transactions and lending, credit-facility terms, and the status of disclosed legal matters.